MediPharm Labs (MLZ) Ratios
1 Followers
MediPharm Labs Ratios
DE:MLZ's free cash flow for Q2 2026 was C$-442.00K. For the 2026 fiscal year, DE:MLZ's free cash flow was decreased by C$-46.00K and operating cash flow was C$-396.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.77 | 3.15 | 3.37 | 5.01 | 7.38 |
| Quick Ratio | 1.96 | 2.32 | 2.46 | 4.18 | 6.15 |
| Cash Ratio | 1.09 | 1.11 | 1.66 | 2.55 | 3.84 |
| Solvency Ratio | -0.67 | -0.77 | -0.97 | -2.86 | -5.34 |
| Operating Cash Flow Ratio | -0.55 | -0.46 | -1.14 | -1.70 | -1.49 |
| Short-Term Operating Cash Flow Coverage | -36.69 | -18.84 | -5.86 | -30.72 | 0.00 |
| Net Current Asset Value | C$ 17.54M | C$ 22.54M | C$ 25.70M | C$ 37.85M | C$ 56.33M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.04 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.04 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.04 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.28 | 1.24 | 1.21 | 1.17 | 1.11 |
| Debt Service Coverage Ratio | -30.72 | -9.01 | -4.13 | -48.88 | -3.68 |
| Interest Coverage Ratio | -133.46 | -18.77 | -50.01 | -952.68 | -4.66 |
| Debt to Market Cap | 0.01 | 0.01 | 0.09 | 0.03 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.01 | 0.00 | 0.04 |
| Net Debt to EBITDA | 1.62 | 1.50 | 1.50 | 0.87 | 0.88 |
| Profitability Margins | |||||
| Gross Profit Margin | 30.95% | 30.52% | 17.71% | -8.65% | -70.22% |
| EBIT Margin | -18.18% | -24.11% | -39.30% | -135.45% | -203.50% |
| EBITDA Margin | -14.50% | -17.92% | -31.69% | -122.47% | -177.56% |
| Operating Profit Margin | -18.63% | -25.76% | -55.21% | -133.53% | -225.31% |
| Pretax Profit Margin | -18.32% | -25.49% | -40.41% | -135.59% | -251.89% |
| Net Profit Margin | -18.32% | -25.49% | -39.57% | -135.57% | -252.41% |
| Continuous Operations Profit Margin | -18.32% | -25.49% | -39.57% | -135.57% | -252.41% |
| Net Income Per EBT | 100.00% | 100.00% | 97.93% | 99.98% | 100.21% |
| EBT Per EBIT | 98.32% | 98.94% | 73.19% | 101.54% | 111.80% |
| Return on Assets (ROA) | -18.07% | -19.90% | -20.46% | -45.78% | -59.33% |
| Return on Equity (ROE) | -23.08% | -24.76% | -24.68% | -53.54% | -65.91% |
| Return on Capital Employed (ROCE) | -23.48% | -25.00% | -34.39% | -52.70% | -58.59% |
| Return on Invested Capital (ROIC) | -23.35% | -24.81% | -32.32% | -52.13% | -58.51% |
| Return on Tangible Assets | -18.35% | -20.22% | -20.80% | -45.81% | -59.36% |
| Earnings Yield | -30.23% | -43.69% | -55.40% | -154.71% | -118.53% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.99 | 5.59 | 5.64 | 1.70 | 1.28 |
| Payables Turnover | 6.61 | 6.88 | 12.77 | 6.79 | 12.36 |
| Inventory Turnover | 3.89 | 3.35 | 2.75 | 3.09 | 3.37 |
| Fixed Asset Turnover | 2.56 | 2.19 | 1.31 | 1.22 | 0.84 |
| Asset Turnover | 0.99 | 0.78 | 0.52 | 0.34 | 0.24 |
| Working Capital Turnover Ratio | 2.25 | 1.74 | 1.04 | 0.47 | 0.38 |
| Cash Conversion Cycle | 99.60 | 121.34 | 168.99 | 278.98 | 363.28 |
| Days of Sales Outstanding | 60.90 | 65.34 | 64.76 | 214.62 | 284.42 |
| Days of Inventory Outstanding | 93.93 | 109.04 | 132.80 | 118.11 | 108.40 |
| Days of Payables Outstanding | 55.24 | 53.04 | 28.58 | 53.75 | 29.54 |
| Operating Cycle | 154.83 | 174.38 | 197.56 | 332.73 | 392.82 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.01 | -0.03 | -0.06 | -0.05 |
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.04 | -0.06 | -0.06 |
| Dividend Paid and CapEx Coverage Ratio | -55.04 | -31.56 | -26.20 | -18.62 | -16.87 |
| Capital Expenditure Coverage Ratio | -55.04 | -31.56 | -26.20 | -18.62 | -16.87 |
| Operating Cash Flow Coverage Ratio | -27.38 | -12.53 | -5.38 | -25.43 | -61.17 |
| Operating Cash Flow to Sales Ratio | -0.12 | -0.12 | -0.37 | -0.73 | -0.61 |
| Free Cash Flow Yield | -20.49% | -20.49% | -54.24% | -87.37% | -30.27% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.32 | -2.29 | -1.81 | -0.65 | -0.84 |
| Price-to-Sales (P/S) Ratio | 0.61 | 0.58 | 0.71 | 0.88 | 2.13 |
| Price-to-Book (P/B) Ratio | 0.76 | 0.57 | 0.45 | 0.35 | 0.56 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.88 | -4.88 | -1.84 | -1.14 | -3.30 |
| Price-to-Operating Cash Flow Ratio | -4.97 | -5.04 | -1.91 | -1.21 | -3.50 |
| Price-to-Earnings Growth (PEG) Ratio | 0.13 | 0.08 | 0.03 | 0.01 | 0.02 |
| Enterprise Value Multiple | -2.56 | -1.75 | -0.76 | 0.15 | -0.32 |
| Enterprise Value | 16.74M | 13.18M | 7.93M | -4.13M | 12.34M |
| EV to EBITDA | -2.56 | -1.75 | -0.76 | 0.15 | -0.32 |
| EV to Sales | 0.37 | 0.31 | 0.24 | -0.19 | 0.57 |
| EV to Free Cash Flow | -2.99 | -2.63 | -0.62 | 0.24 | -0.88 |
| EV to Operating Cash Flow | -3.04 | -2.71 | -0.64 | 0.26 | -0.93 |
| Tangible Book Value Per Share | 0.08 | 0.10 | 0.14 | 0.20 | 0.33 |
| Shareholders’ Equity Per Share | 0.09 | 0.11 | 0.15 | 0.20 | 0.33 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.02 | 0.00 | -0.00 |
| Revenue Per Share | 0.11 | 0.10 | 0.09 | 0.08 | 0.09 |
| Net Income Per Share | -0.02 | -0.03 | -0.04 | -0.11 | -0.22 |
| Tax Burden | 1.00 | 1.00 | 0.98 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.06 | 1.03 | 1.00 | 1.24 |
| Research & Development to Revenue | 0.00 | 0.01 | 0.01 | 0.05 | 0.06 |
| SG&A to Revenue | 0.48 | 0.54 | 0.65 | 0.83 | 0.85 |
| Stock-Based Compensation to Revenue | 0.03 | 0.02 | 0.06 | 0.13 | 0.11 |
| Income Quality | 0.67 | 0.45 | 0.94 | 0.54 | 0.24 |
Currency in CAD
